Focus Partners Wealth Decreases Holdings in Boston Scientific Corporation $BSX

Key Points

• Focus Partners Wealth reduced its holdings in Boston Scientific by 3.4%, owning 366,244 shares valued at approximately $36.95 million after selling 13,009 shares in the first quarter.
• Hedge funds like NS Partners Ltd and Ascent Group LLC increased their stakes in Boston Scientific, with holdings now primarily dominated by institutional investors, owning 89.07% of the stock.
• Boston Scientific reported $0.75 EPS for the last quarter, exceeding expectations, and has an average target price of $117.79 from analysts who mostly recommend a Buy rating.

Focus Partners Wealth trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 3.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 366,244 shares of the medical equipment provider's stock after selling 13,009 shares during the quarter. Focus Partners Wealth's holdings in Boston Scientific were worth $36,947,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in BSX. NS Partners Ltd boosted its stake in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider's stock valued at $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Bank Pictet & Cie Europe AG boosted its stake in Boston Scientific by 40.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock valued at $6,529,000 after acquiring an additional 21,173 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Boston Scientific by 18.8% in the first quarter. Oppenheimer & Co. Inc. now owns 39,523 shares of the medical equipment provider's stock valued at $3,987,000 after acquiring an additional 6,264 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new stake in Boston Scientific in the first quarter valued at approximately $8,234,000. Finally, Ascent Group LLC boosted its stake in Boston Scientific by 226.5% in the first quarter. Ascent Group LLC now owns 49,942 shares of the medical equipment provider's stock valued at $5,038,000 after acquiring an additional 34,645 shares in the last quarter. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of Boston Scientific stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the completion of the transaction, the director owned 2,081 shares of the company's stock, valued at approximately $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the completion of the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock worth $18,397,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 2.6%

NYSE BSX opened at $105.32 on Thursday. The company has a fifty day simple moving average of $104.88 and a two-hundred day simple moving average of $102.24. The stock has a market cap of $156.06 billion, a P/E ratio of 62.69, a P/E/G ratio of 2.60 and a beta of 0.65. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to analysts' expectations of $4.89 billion. During the same quarter last year, the company posted $0.62 earnings per share. The firm's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on BSX shares. Royal Bank Of Canada restated an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Truist Financial raised their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 24th. Needham & Company LLC restated a "buy" rating and issued a $115.00 target price on shares of Boston Scientific in a research note on Wednesday, May 28th. Oppenheimer upgraded shares of Boston Scientific from a "market perform" rating to an "outperform" rating and raised their target price for the company from $118.00 to $125.00 in a research note on Monday. Finally, Jefferies Financial Group restated a "hold" rating on shares of Boston Scientific in a research note on Monday, July 21st. Three investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $117.79.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.